SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3uFrj6t
via IFTTT